We rank companies based on fund manager, research analyst and news sentiment
XRTX

XORTX Therapeutics
XRTX

$3
2.3%
 

About: XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Employees: 3

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

1,638,913% more capital invested

Capital invested by funds: $9.8K [Q3] → $161M (+$161M) [Q4]

138.11% more ownership

Funds ownership: 0.09% [Q3] → 138.2% (+138.11%) [Q4]

20% less funds holding

Funds holding: 5 [Q3] → 4 (-1) [Q4]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$14
367%
upside
Avg. target
$14
367%
upside
High target
$14
367%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Alliance Global Partners
James Molloy
367%upside
$14
Buy
Maintained
4 Jan 2024

Financial journalist opinion